SCYNEXIS
NASDAQ: SCYX · Jersey City, NJ

Clinical-stage · Rare disease

Two programs.
One new BARDA contract.

Both programs are investigational. BARDA could provide up to ~$214M for SCY-247 if all options are exercised.

Figure 1BARDA Contract · SCY-247
POTENTIAL, IF ALL OPTIONS ARE EXERCISED UP TO ~$214M ~$18.5M INITIAL BASE PERIOD BAR LENGTHS TO SCALE · COST-SHARE · UP TO 10 YEARS
Potential BARDA funding
Up to ~$214M If all options are exercised

Fig. 02 · SCY-770 · ADPKD

A direct AMPK
activator for ADPKD.

Investigational oral SCY-770 is in development for autosomal dominant polycystic kidney disease (ADPKD).

Figure 2SCY-770 · Stated Mechanism
SCY-770 AMPK mTOR cAMP CYST CELL GROWTH MECHANISM AS DESCRIBED BY THE COMPANY
Diagnosed U.S. ADPKD patients
~140,000 FDA Orphan Drug Designation

Fig. 03 · SCY-247 · Antifungal

A new-class antifungal,
oral and IV.

Investigational SCY-247 is in development for invasive candidiasis and prevention of invasive fungal infections.

Figure 3SCY-247 · Development Path
ORAL · PHASE 1 REPORTED SEP 2025 IV · PHASE 1 DOSING COMPLETE PHASE 2 INVASIVE CANDIDIASIS BARDA INITIAL BASE PERIOD SUPPORTS PHASE 2
FDA designations granted
3 Orphan · QIDP · Fast Track

Fig. 04 · Cash & Investments

Runway expected
into 2029.

Cash, cash equivalents and investments were $71.1M at June 30, 2026, after a $36.9M net private placement (closed Apr 1).

Figure 4Cash, Equivalents & Investments
$56.3M DEC 31, 2025 $71.1M JUN 30, 2026
Expected cash runway
Into 2029 Not expected to change with BARDA
TWO INVESTIGATIONAL PROGRAMS · RARE DISEASE
Read the Investor Overview
SCY-770 & SCY-247 are investigational, not FDA-approved. Forward-looking statements: BARDA options, runway, timing.